Alpha-synuclein and Parkinson's disease: a proteomic view

Area of Science:

• Neuroscience
• Biochemistry
• Genetics

Background:

• Parkinson's disease (PD) is a neurodegenerative disorder affecting 2% of adults over 65.
• Pathologically, PD is defined by alpha-synuclein protein aggregates within neurons.
• The precise causes of substantia nigra neuron degeneration in PD remain incompletely understood.

Purpose of the Study:

• To review the application of proteomic methodologies in studying Parkinson's disease models.
• To focus on the role of alpha-synuclein in PD pathogenesis.
• To identify novel molecular features associated with early-stage PD.

Main Methods:

• Review of proteomic studies utilizing cellular models of PD.
• Analysis of proteomic data from animal models of PD.
• Focus on investigations involving alpha-synuclein aggregation and dopamine homeostasis.

Main Results:

• Proteomic analyses confirmed established PD pathogenesis theories, including mitochondrial dysfunction, oxidative stress, and proteasome system failure.
• New insights into presymptomatic PD stages were uncovered.
• Dysregulation of cytoskeletal proteins was identified as a potential early feature of PD.

Conclusions:

• Proteomics provides valuable tools for dissecting PD mechanisms in model systems.
• Alpha-synuclein aggregation is a central pathological hallmark confirmed by proteomic studies.
• Cytoskeletal protein alterations may represent critical early events in PD development, offering potential diagnostic or therapeutic targets.